MarketCap
Facebook
X
Telegram
Conformis Net Income | CFMS
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Conformis
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -50.5 M | -2.41 M | -24.3 M | -5.43 M | -9.87 M | -11.9 M | -57.6 M | -57.2 M | -45.7 M | -47.9 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.41 M | -57.6 M | -31.3 M |
Quarterly Net Income Conformis
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -13 M | -9.57 M | - | -15.2 M | -15.5 M | -16 M | - | -13 M | 38 M | -11.5 M | -6.62 M | -6.18 M | -2.14 M | -9.35 M | -5.43 M | -8.7 M | -6.76 M | -7.58 M | -9.87 M | -7.44 M | -14.1 M | -12 M | -11.9 M | -12.5 M | -12.1 M | -17.2 M | -15.7 M | -12.8 M | -14.1 M | -15 M | -15 M | -17.1 M | -10.9 M | -14.3 M | -12.1 M | -10.4 M | -10.5 M | -12.7 M | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 38 M | -17.2 M | -10.2 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Tandem Diabetes Care
TNDM
|
-205 M | $ 16.35 | -1.03 % | $ 1.11 B |  USA |
 |
Inspire Medical Systems
INSP
|
145 M | $ 71.07 | -0.38 % | $ 2.09 B | USA |
 |
IRIDEX Corporation
IRIX
|
-4.44 M | $ 0.77 | 1.68 % | $ 13 M | USA |
 |
IRadimed Corporation
IRMD
|
22.5 M | $ 87.81 | -0.49 % | $ 1.12 B | USA |
 |
Viemed Healthcare
VMD
|
15.4 M | $ 9.75 | -0.51 % | $ 379 M | USA |
 |
Varex Imaging Corporation
VREX
|
-70.3 M | $ 18.42 | 0.11 % | $ 763 M | USA |
 |
Vivos Therapeutics
VVOS
|
-21.2 M | $ 0.13 | -4.2 % | $ 1.34 M | USA |
 |
AdaptHealth Corp.
AHCO
|
-70.8 M | $ 6.1 | -0.41 % | $ 824 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
-517 M | $ 11.84 | -11.18 % | $ 908 M | USA |
 |
Inogen
INGN
|
22.7 M | $ 6.67 | -0.3 % | $ 177 M | USA |
 |
InMode Ltd.
INMD
|
93.8 M | $ 14.03 | -0.78 % | $ 907 M |  Israel |
 |
GenMark Diagnostics, Inc.
GNMK
|
-18.6 M | - | - | $ 1.77 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-12.3 M | - | -5.86 % | $ 30.6 M | USA |
 |
Medtronic PLC
MDT
|
4.8 B | $ 93.03 | -1.71 % | $ 119 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.07 B | $ 88.4 | 0.12 % | $ 51.7 B | USA |
 |
Myomo
MYO
|
-15.6 M | $ 1.26 | 0.39 % | $ 52.7 M | USA |
 |
Beyond Air
XAIR
|
-33.2 M | $ 2.34 | 6.85 % | $ 19.4 B | USA |
 |
Globus Medical
GMED
|
538 M | $ 78.68 | -0.35 % | $ 10.6 B | USA |
 |
Insulet Corporation
PODD
|
247 M | $ 141.9 | -0.52 % | $ 9.98 B | USA |
 |
Xtant Medical Holdings
XTNT
|
4.97 M | $ 0.3 | -2.31 % | $ 41.9 M | USA |
 |
Sensus Healthcare
SRTS
|
-7.72 M | $ 2.86 | 4.0 % | $ 46.7 M | USA |
 |
Tactile Systems Technology
TCMD
|
19.1 M | $ 23.28 | -1.02 % | $ 532 M | USA |
 |
Penumbra
PEN
|
178 M | $ 323.56 | -0.25 % | $ 12.6 B | USA |
 |
Stryker Corporation
SYK
|
849 M | $ 297.6 | -2.23 % | $ 114 B | USA |
 |
Zimmer Biomet Holdings
ZBH
|
705 M | $ 94.86 | -1.19 % | $ 18.8 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
-638 K | $ 9.33 | 5.9 % | $ 680 M | Israel |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | USA |
 |
Delcath Systems
DCTH
|
2.7 M | $ 14.7 | -0.41 % | $ 527 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
-75 M | $ 0.38 | -6.87 % | $ 24.6 M | Israel |
 |
OrthoPediatrics Corp.
KIDS
|
-39.6 M | $ 23.84 | 1.45 % | $ 559 M | USA |
 |
MiMedx Group
MDXG
|
48.6 M | $ 3.74 | -11.58 % | $ 553 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-19 M | - | - | $ 162 M |  France |
 |
Soliton, Inc.
SOLY
|
-14.5 M | - | -1.42 % | $ 435 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-10.9 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
-17.4 M | - | - | $ 462 M | USA |
 |
Intersect ENT, Inc.
XENT
|
-72.3 M | - | - | $ 955 M | USA |
 |
CryoLife, Inc.
CRY
|
-16.7 M | - | -4.14 % | $ 702 M | USA |
 |
Avanos Medical
AVNS
|
-72.9 M | $ 24.99 | - | $ 1.16 B | USA |
 |
Aziyo Biologics
AZYO
|
53.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
BioSig Technologies
BSGM
|
-463 M | - | 37.08 % | $ 85.7 M | USA |
 |
Dynatronics Corporation
DYNT
|
-10.9 M | - | 14.99 % | $ 929 K | USA |
 |
Second Sight Medical Products
EYES
|
26.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
FONAR Corporation
FONR
|
8.33 M | - | - | $ 140 M | USA |
 |
GBS
GBS
|
-12.4 M | - | -0.57 % | $ 7.12 M | USA |
 |
NanoVibronix
NAOV
|
-18.2 M | - | - | $ 1.08 M | USA |
 |
Ra Medical Systems
RMED
|
-17.2 M | - | 10.0 % | $ 610 K | USA |
 |
ReWalk Robotics Ltd.
RWLK
|
-19.9 M | - | 7.07 % | $ 66.1 M | Israel |
 |
STRATA Skin Sciences
SSKN
|
-6.26 M | - | - | $ 6.6 M | USA |